Abstract 21P
Background
Neoadjuvant treatment (NAT) refers to the treatment that is administered before surgery for the treatment of cancer. For the last few years the medical community noticed that achieving complete pathological response (pCR), for HER2+ breast cancer patients, after the NAT equates to a long-term surrogate point, which has pushed for the development of treatment strategies based of neoadjuvant use of trastuzumab and pertuzumab. We implemented an institutional protocol in 2018 to treat HER2+ breast cancer patients that had tumours larger than 2cm and/or axillary disease that had had included anthracyclins, taxanes, trastuzumab and pertuzumab on their NAT regimen. The main goal was to prospectively analyse the effect of this neoadjuvant regimen on pCR (ypT0/is, ypN0/is), as well as on how often does NAT help with breast conservation.
Methods
This non-randomized prospective study was performed in two medical oncology departments in Portugal. It included HER2+ breast cancer patients that had tumours larger than 2cm and/or axillary disease that have been being treated since 2018. These patients were put on the following treatment scheme: 4 cycles of doxorrubicin and cyclofosfamid, followed by 12 doses of standard paclitaxel plus four standard trastuzumab and pertuzumab cycles.
Results
A total of 38 patients were included in the study. The median age: 54 years; 17 patients had stage II cancer and 21 patients stage III. 26 patients had a ki67 >20%. pCR was achieved in 60,5% of the patients, 58,6 % in the hormonal receptor (HR) positive subgroup and 66,7% in HR-negative patients. 57,9% of the patients received breast conservative surgery and 65,9% received axillary dissection. Only one patient didn’t complete the protocol by own choice and no cardiac toxicity was detected on any patient.
Conclusions
Our results are consistent with those published in previous studies in terms of pCR rate and toxicity, however there was a high number of axillar dissections and for that reason we are working in an institutional protocol for the management of the axillary disease after NAT. Long term follow up is necessary to understand the real impact of pCR and to search for predictive indicators of the response to NAT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session